MAPS study
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific launches a 630-patient clinical trial to evaluate the value of target aneurysm recurrence as an endpoint for trials of endovascular devices to treat brain aneurysms. The Matrix and Platinum Science (MAPS) trial randomizes patients with brain aneurysms to be treated with either Boston Scientific's GDC detachable coil or its Matrix2 detachable coil. The primary endpoint of the 50-center trial is target aneurysm recurrence, defined as a composite of target aneurysm reintervention, target aneurysm rupture or rerupture, and death...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.